Hospira announced that the European Commission has approved its biosimilar version of Remicade from Johnson & Johnson and Merck . The approval of the new drug, called Inflectra, marks the first time a monoclonal antibody has had a true generic competitor. It could also threaten a sizable chunk of the $2.1 billion in European sales for Remicade, which brought in $8.22 billion worldwide in 2012. The approval is an excellent development for companies seeking to incorporate biosimilar pipelines into their businesses and could impede the growth of some of the world's most successful drugs. However, there are still plenty of questions that remain unanswered. So how big of an opportunity exists for investors?
Major world markets have set the stage for a thriving biosimilar industry. Source: Sandoz.
The start of something BIG
Why is biosimilar legislation needed in the first place? Believe it or not, biologic medicines are generally not included in previous pharmaceutical patent laws. When they are, it is usually a gray area. So the fact that major markets are getting their regulatory ducks in a row is amazing news. According to Sandoz, the generic drug business of Novartis , originator biologics with sales totaling $100 billion will lose exclusivity by 2020. The world's leading biosimilar company also claims that "by 2017 up to 30% of the pharmaceutical industry pipeline will be comprised of biologics."
That means the market for generic drugs could be about to explode -- and create alternative revenue streams for companies. Here are several leading biologics in the crosshairs of generic manufacturers.
2012 Worldwide Sales
Patent Expiration (EU, U.S.)
Source: Genetic Engineering & Biotechnology News, *includes drugs in development.
Sandoz and Hospira are developing biosimilars for several of the world's best-selling biologics, including Herceptin and Rituxan from Roche, Neulasta and Neupogen from Amgen , and of course Remicade. According to Reuters, analysts believe Hospira's Inflectra could bring in over $200 million annually. Expect similar figures -- or higher -- to be floated around for future biosimilars, especially those that are first-to-market.
Is Johnson & Johnson doomed? Not quite. Remicade is still protected in the United States (Merck owns European rights), but it should be able to replace revenue eventually lost to generics with growth elsewhere in its portfolio. Next generation immunology drug Stelara generated sales of $371 million in the first half of 2013, which represented growth of 50% from the previous year. Expanded treatment approvals should keep the growth going for the foreseeable future.
The flip side
Other companies are seeking to join the fight against biosimilar competition by throwing their own hats into the ring. Merck was once labeled as one of the top would-be biosimilar manufacturers, but has discontinued several high-profile programs including those for generic versions of Aranesp and Enbrel. Key personnel moves in the past year may help return confidence in the company's biosimilar prospects, but investors are awaiting real results now.
Similarly, Amgen faces some pretty tough generic competition to multiple blockbuster drugs in multiple markets, but is looking to biosimilars to generate billions in revenue in the next decade. It has had much better success than Merck, however, and would be my top pick for the industry. The biotech leader is developing generic versions of Herceptin, Humira, Remicade, and Rituxan, among others. Couple the company's expertise in manufacturing with its marketing know-how and the results could be scary.
What are some of the questions facing the biosimilar industry? For starters, can the Food and Drug Administration in the United States respond to the industry's pleas for a clear path forward for biosimilar development? Earlier this summer, eight companies submitted comments seeking clarification on the FDA draft guidance for meetings between the agency and biosimilar developers. It is by no means a nail in the coffin and biosimilars will surely be approved in the United States once patents expire, but for now companies and investors are focused on the European market.
Additionally, how much cheaper will biosimilars be compared to innovator biologics? Development and manufacturing of biosimilars is much more expensive than that of generic small molecule drugs. Will that eat away at any cost advantages? If so, by how much? Furthermore, since no two biologic medicines are exactly identical, will doctors be hesitant to prescribe biosimilars over drugs with long safety records such as Remicade?
The biosimilar industry will experience growing pains as would any other high-growth, high-impact industry. I am still sold on the opportunity presented to investors who keep up with regulatory and development updates. In fact, it could become a hidden gem for biotech investors, since I rarely see analysts describe the potential impacts of biosimilar programs to Novartis, Hospira, and Amgen. Increasing revenue, additional cash flow, and improved market share could await. What's not to like?
Not convinced of the opportunity in biosimilars? Looking for ways to diversify into dividend-paying stocks? The Motley Fool's special report "Secure Your Future With 9 Rock-Solid Dividend Stocks" is a great way to kick-start your search. Just click here to get your free copy today.
The article Will This Biotech Approval Start a $100 Billion Trend? originally appeared on Fool.com.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.